カテゴリ： GlobalData, アメリカ, 企業調査

Revance Therapeutics Inc (RVNC)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Revance Therapeutics Inc (RVNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013539
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc (RVNC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Revance Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 13
Venture Financing 14
Revance Therapeutics Raises US$10 Million In Venture Financing 14
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 15
Revance Therapeutics Secures US$40 Million In Venture Financing 17
ReVance Therapeutics Secures US$5 Million In Financing Round 18
Equity Offering 19
Revance Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 19
Revance Therapeutics Raises USD134.6 Public Offering of Shares 20
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 22
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 23
Revance Therapeutics Completes IPO For US$110.4 Million 25
Revance Therapeutics Inc – Key Competitors 27
Revance Therapeutics Inc – Key Employees 28
Revance Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 02, 2017: Revance Releases Third Quarter 2017 Results 30
Aug 03, 2017: Revance Releases Second Quarter 2017 Results 31
May 09, 2017: Revance Releases First Quarter 2017 Results 32
Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 33
Nov 03, 2016: Revance Releases Third Quarter 2016 Results 35
Aug 04, 2016: Revance Releases Second Quarter 2016 Results 36
May 09, 2016: Revance Releases First Quarter 2016 Results 37
Mar 02, 2016: Revance Releases Fourth Quarter and Full Year 2015 Results 38
Corporate Communications 39
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 39
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 40
Jul 05, 2016: Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors 41
Product News 42
07/14/2016: Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines 42
01/12/2017: Revance Therapeutics Enters into $6.4M Settlement with City of Warren Police and Fire Retirement System 43
Clinical Trials 44
Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 44
May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 46
May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 48
Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 49
Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 50
Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 51
Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 52
Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 53
Dec 12, 2016: Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial 54
Dec 07, 2016: Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 56
Nov 03, 2016: Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis 57
Jun 13, 2016: Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines 58
Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 59
Other Significant Developments 61
Jan 07, 2016: Revance Specifies 2016 Clinical Program Milestones 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Revance Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Revance Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 13
Revance Therapeutics Raises US$10 Million In Venture Financing 14
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 15
Revance Therapeutics Secures US$40 Million In Venture Financing 17
ReVance Therapeutics Secures US$5 Million In Financing Round 18
Revance Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 19
Revance Therapeutics Raises USD134.6 Public Offering of Shares 20
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 22
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 23
Revance Therapeutics Completes IPO For US$110.4 Million 25
Revance Therapeutics Inc, Key Competitors 27
Revance Therapeutics Inc, Key Employees 28
Revance Therapeutics Inc, Subsidiaries 29

★海外企業調査レポート[Revance Therapeutics Inc (RVNC)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Mapletree Investments Pte Ltd：企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Emirates Telecommunications Group Company PJSC：企業のM&A・事業提携・投資動向
    Emirates Telecommunications Group Company PJSC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Emirates Telecommunications Group Company PJSC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descriptio …
  • Yungjin Pharm Co Ltd (003520)：企業の財務・戦略的SWOT分析
    Summary Yungjin Pharm Co Ltd (Yungjin), a subsidiary of KT&G Corp is a pharmaceutical company that develops, manufactures and distributes active pharmaceutical ingredients, formulations and tonic drinks. The company provides API products such as cephalosporins and other general products. It also off …
  • Litha Healthcare Group Ltd-医療機器分野：企業M&A・提携分析
    Summary Litha Healthcare Group Ltd (Litha Healthcare), formerly Myriad Medical Holdings Limited, a subsidiary of Endo International plc is a healthcare company that provides its services to public and private hospitals, pharmacies, general, allied practitioners, and government healthcare programmes. …
  • Depomed, Inc.：企業の戦略・SWOT・財務情報
    Depomed, Inc. - Strategy, SWOT and Corporate Finance Report Summary Depomed, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Aspial Corporation Ltd (A30)：企業の財務・戦略的SWOT分析
    Aspial Corporation Ltd (A30) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Vectura Group Plc (VEC)-医療機器分野：企業M&A・提携分析
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • Valvoline Inc (VVV)：企業の財務・戦略的SWOT分析
    Valvoline Inc (VVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Tractebel Engineering：企業の戦略的SWOT分析
    Tractebel Engineering - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Enbridge Inc (ENB)：企業の財務・戦略的SWOT分析
    Enbridge Inc (ENB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Cellmid Ltd (CDY)-医療機器分野：企業M&A・提携分析
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd is a developer of therapies and diagnostic tests. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair …
  • University of Pennsylvania：企業のM&A・事業提携・投資動向
    University of Pennsylvania - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's University of Pennsylvania Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Oriental Land Co., Ltd.：企業の戦略・SWOT・財務情報
    Oriental Land Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Oriental Land Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tata Advanced Systems Ltd：企業の戦略・SWOT・財務情報
    Tata Advanced Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Tata Advanced Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Polski Koncern Naftowy ORLEN SA：企業の戦略・SWOT・財務情報
    Polski Koncern Naftowy ORLEN SA - Strategy, SWOT and Corporate Finance Report Summary Polski Koncern Naftowy ORLEN SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Kansas Electric Power Cooperative, Inc.：企業の戦略的SWOT分析
    Kansas Electric Power Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Biocept Inc (BIOC)-医療機器分野：企業M&A・提携分析
    Summary Biocept Inc (Biocept) is a developer of diagnostic solutions. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for various solid tumor cancers. Biocept offers related instrumentation, OncoCEE technology, and analytica …
  • Vivartia Holdings SA.：戦略・SWOT・企業財務分析
    Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report Summary Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fortis Inc (FTS)：石油・ガス：M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Swagelok Company：企業の戦略・SWOT・財務情報
    Swagelok Company - Strategy, SWOT and Corporate Finance Report Summary Swagelok Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆